登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Safety and Preliminary Efficacy of a Metabolically Armed Chimeric Antigen Receptor T Cell Therapy Targeting EGFRvIII for Recurrent Glioblastoma
ClinicalTrials.gov 上登记的一项胶质瘤开放试验,由浙江大学医学院附属第二医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07244666,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 8
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(8 项)收起清单
19 岁 至 70 岁;性别:不限
登记记录的入选字段
Previously diagnosed with glioblastoma through histopathological/ molecular pathology reports.
入选标准第 4 条
Disease progression or recurrence confirmed by histopathology or imaging (defined as per RANO2.0 criteria as either progression/recurrence or lesions with abnormal enhancement accompanied by hypermetabolism or hyperperfusion changes) that are eligible for use when no standard treatment is available at enrollment;
入选标准第 5 条
At least 6 weeks must have passed since the completion of the last nitrosourea-based chemotherapy regimen;
入选标准第 21 条
Karnofsky Performance Status (KPS) ≥60 points, ECOG score ≤2 (reconfirmed before CAR-T infusion);
入选标准第 7 条
Complete blood count [must meet the following criteria within 24 hours prior to whole blood collection: avoid transfusions, platelet transfusions, and colony-stimulating factors (excluding recombinant erythropoietin) within 7 days before testing]:
入选标准第 12 条
Blood Biochemistry: Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) ≤2.5 times ULN; serum creatinine ≤1.6 mg/dL; total bilirubin ≤1.5 mg/dL (except for subjects with GBM liver involvement and Gilbert syndrome patients, whose total bilirubin must be <3.0 mg/dL).
入选标准第 13 条
Measurable tumor lesions according to the Response Assessment in Neuro-Oncology (RANO 2.0);
入选标准第 8 条
Subjects with active hepatitis B (defined as hepatitis B surface antigen positivity or core antibody positivity with HBV DNA >1000 copies/mL) or active hepatitis C (HCV RNA positive);
排除标准第 8 条
Subjects testing positive for HIV antibodies or Treponema pallidum antibodies;
排除标准第 9 条
Malignancies without recurrence or treatment within the past 2 years.
排除标准第 18 条
All male subjects and women of childbearing age must agree to use highly effective contraceptive methods for at least 12 months after LMC005 infusion until two consecutive PCR tests show no residual CAR-T cells in the body.
入选标准第 24 条
Pregnant or lactating female subjects (women of childbearing potential with a positive pregnancy test result during screening);
排除标准第 19 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义)。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07244666,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
All subjects or their legal guardians must personally sign the written informed consent form approved by the ethics committee in writing before starting any screening procedures; Age between 18 and 70 years old (inclusive), both male and female; Confirmed diagnosis of recurrent glioblastoma, as specified below: Previously diagnosed with glioblastoma through histopathological/ molecular pathology reports. Disease progression or recurrence confirmed by histopathology or imaging (defined as per RANO2.0 criteria as either progression/recurrence or lesions with abnormal enhancement accompanied by hypermetabolism or hyperperfusion changes) that are eligible for use when no standard treatment is available at enrollment; Positive EGFRvIII expression detected in tumor cells (confirmed through next-generation sequencing), and only eligible for patients who have previously received EGFRvIII-targeted therapy and relapsed, provided the EGFRvIII remains positive in post-relapse tumor samples; Karnofsky Performance Status (KPS) ≥60 points, ECOG score ≤2 (reconfirmed before CAR-T infusion); Measurable tumor lesions according to the Response Assessment in Neuro-Oncology (RANO 2.0); Adequate peripheral blood obtainable via venipuncture with no contraindications for lymphocyte collection, and sufficient peripheral blood cells collected for CAR-T cell preparation; Expected life expectancy ≥12 weeks; Adequate organ function (reconfirmed before CAR-T infusion): Complete blood count [must meet the following criteria within 24 hours prior to whole blood collection: avoid transfusions, platelet transfusions, and colony-stimulating factors (excluding recombinant erythropoietin) within 7 days before testing]: Blood Biochemistry: Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) ≤2.5 times ULN; serum creatinine ≤1.6 mg/dL; total bilirubin ≤1.5 mg/dL (except for subjects with GBM liver involvement and Gilbert syndrome patients, whose total bilirubin must be <3.0 mg/dL). Serology: Human immunodeficiency virus (HIV) antibody seronegative. The hepatitis B antigen test is negative, and the hepatitis C antibody test is negative. If the hepatitis C antibody test is positive, reverse transcription polymerase chain reaction (RT-PCR) must be performed to detect the presence of hepatitis B antigen and confirm that the hepatitis C virus (HCV) RNA is negative. Lung function: normal or grade 1 dyspnea according to CTCAE, SaO2 ≥ 92% in indoor air environment. Cardiac function: left ventricular ejection fraction (LVEF) ≥40% by echocardiography or radionuclide activity angiography (MUGA) within 1 month of enrollment. Coagulation function (at least including PT, APTT and INR) is within the normal range. Participants using the following medications must meet the following criteria: Corticosteroids: Treatment doses of corticosteroids must be discontinued 2 weeks prior to starting administration. However, physiological replacement doses of corticosteroids are permitted (hydrocortisone or equivalent <6-12 mg/mm²/day); At least 8 weeks must have elapsed between completing the last radiotherapy session and initiating treatment; At least 6 weeks must have passed since the completion of the last nitrosourea-based chemotherapy regimen; At least 14 days must have elapsed since the completion of the last temozolomide or other chemotherapy regimens before treatment initiation. If the subject has recently received targeted therapy and adverse events related to their targeted drug have resolved to baseline levels, screening may begin after a 2-week washout period (for bevacizumab, a total of 4 weeks of washout is required after confirming no bleeding caused by gastrointestinal ulcers). For long-term chronic low-grade (≤2) adverse events such as paronychia, eligibility will be determined by the investigator. The investigator determines that the subject has recovered from toxicity caused by prior anti-tumor treatment to grade 1 or below (except for special grade 2 or below toxicity that could not be recovered in a short period of time, such as hair loss), and is suitable for pre-treatment chemotherapy and CAR-T cell therapy. All male subjects and women of childbearing age must agree to use highly effective contraceptive methods for at least 12 months after LMC005 infusion until two consecutive PCR tests show no residual CAR-T cells in the body. Patients in the intraventricular injection group must additionally meet the following criteria: The investigator determines that the intracranial tumor is suitable for Ommaya sac implantation.排除标准:Exclusion Criteria:
Subjects exhibiting other severe central nervous system disorders deemed by the investigator to be unrelated to the indication; Subjects anticipated to require systemic corticosteroid use within three months due to disease progression related to the indication; Subjects who have received the following medications: Corticosteroids at therapeutic doses (defined as prednisone >20 mg/day, hydrocortisone >20 mg/day, methylprednisolone >4 mg/day, dexamethasone >0.75 mg/day, betamethasone >0.5 mg/day) within 7 days prior to leukapheresis or within 72 hours before CAR-T cell administration; Lymphocyte-toxic chemotherapy (e.g., cyclophosphamide, ifosfamide, bendamustine) administered within 2 weeks prior to leukapheresis; Investigational drugs from other clinical trials used within 4 weeks prior to blood collection. Exception: Patients whose prior trial medications were ineffective or whose disease progressed during the trial, provided at least 3 half-lives have elapsed since the last dose before leukapheresis; Radiotherapy received within 4 weeks prior to blood collection. Subjects with active hepatitis B (defined as hepatitis B surface antigen positivity or core antibody positivity with HBV DNA >1000 copies/mL) or active hepatitis C (HCV RNA positive); Subjects testing positive for HIV antibodies or Treponema pallidum antibodies; Subjects with uncontrolled acute life-threatening bacterial, viral, or fungal infections (e.g., positive blood culture ≤72 hours prior to LMC005 infusion); Subjects with unstable angina and/or myocardial infarction within 6 months prior to signing informed consent; or subjects with severe stroke or deep venous thrombosis (DVT) within 12 months prior to signing informed consent; Subjects with a history of or concurrent malignant tumors, except those meeting the following criteria: Surgically excised non-melanoma skin cancer; Curatively treated carcinoma in situ of the cervix; Localized prostate cancer; Low-stage bladder cancer; Ductal carcinoma in situ of the breast; Malignancies without recurrence or treatment within the past 2 years. Pregnant or lactating female subjects (women of childbearing potential with a positive pregnancy test result during screening); Subjects with active autoimmune diseases (e.g., Guillain-Barré syndrome, systemic lupus erythematosus); Subjects with a history of QT interval prolongation or other significant cardiac diseases; Subjects with contraindications to MRI scanning, including embedded metallic materials/devices (e.g., pacemakers); Other circumstances identified by the investigator as rendering the subject unsuitable for this study (e.g., poor compliance).
引自 ClinicalTrials.gov, NCT07244666, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07244666,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。